Will Shorter EU Regulatory Timelines Mean Unfeasible Joint Clinical Assessment Timelines?
Executive Summary
Faster regulatory reviews proposed in the European Commission’s pharmaceutical reform package could impact the EU-level joint clinical assessments that go live from 2025.